Atlas Trials

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Clinical trial NCT05821686 · NOT_YET_RECRUITING

Trial details

NCT number
NCT05821686
Sponsor
Nova Scotia Health Authority
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2026-01-02
Primary completion
2028-04-01
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.